1
|
Nappini S, D'Amario L, Favaro M, Dal Zilio S, Salvador F, Betz-Güttner E, Fondacaro A, Píš I, Romanzin L, Gambitta A, Bondino F, Lazzarino M, Magnano E. Soft x-ray spectroscopies in liquids and at solid-liquid interface at BACH beamline at Elettra. Rev Sci Instrum 2021; 92:015115. [PMID: 33514239 DOI: 10.1063/5.0025326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 12/15/2020] [Indexed: 06/12/2023]
Abstract
The beamline for advanced dichroism of the Istituto Officina dei Materiali-Consiglio Nazionale delle Ricerche, operating at the Elettra synchrotron in Trieste (Italy), works in the extreme ultraviolet-soft x-ray photon energy range with selectable light polarization, high energy resolution, brilliance, and time resolution. The beamline offers a multi-technique approach for the investigation of the electronic, chemical, structural, magnetic, and dynamical properties of materials. Recently, one of the three end stations has been dedicated to experiments based on electron transfer processes at the solid/liquid interfaces and during photocatalytic or electrochemical reactions. Suitable cells to perform soft x-ray spectroscopy in the presence of liquids and reagent gases at ambient pressure were developed. Here, we present two types of static cells working in transmission or in fluorescence yield and an electrochemical flow cell that allows us to carry out cyclic voltammetry in situ and electrodeposition on a working electrode and to study chemical reactions under operando conditions. Examples of x-ray absorption spectroscopy measurements performed under ambient conditions and during electrochemical experiments in liquids are presented.
Collapse
Affiliation(s)
- S Nappini
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| | - L D'Amario
- Freie Universität Berlin, Department of Physics Arnimallee 14, 14195 Berlin-Dahlem, Germany
| | - M Favaro
- Institute for Solar Fuels, Helmholtz-Zentrum Berlin für Materialien und Energie GmbH, Hahn-Meitner-Platz 1, 14109 Berlin, Germany
| | - S Dal Zilio
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| | - F Salvador
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| | - E Betz-Güttner
- Università degli Studi di Trieste, Physics Department, P.le Europa 1, 34127 Trieste, Italy
| | - A Fondacaro
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| | - I Píš
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| | - L Romanzin
- Elettra-Sincrotrone Trieste, Area Science Park, 34149 Basovizza, Trieste, Italy
| | - A Gambitta
- Elettra-Sincrotrone Trieste, Area Science Park, 34149 Basovizza, Trieste, Italy
| | - F Bondino
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| | - M Lazzarino
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| | - E Magnano
- IOM CNR Laboratorio TASC, 34149 Basovizza, TS, Italy
| |
Collapse
|
2
|
Zanello A, Mazzega E, Caragnano A, Bulfoni M, Sponga S, Livi U, Battistella A, Lazzarino M, Cesselli D, Beltrami AP. P752Pericyte/mural cells of ischemic human hearts show impairment of mechanotransduction, attenuating YAP signaling. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
The Hippo pathway, that is upregulated in human heart failure, can restrain cardiac regeneration and impair arteriogenesis, preventing the nuclear translocation of the transcriptional coactivator YAP. Actin dynamics and mechanotransduction pathways are critical regulators of YAP subcellular localization.
Aim
To investigate if cardiac pathology alters mechanotransduction pathways, modulating the nucleocytoplasmic shuttling of YAP.
Methods and results
PDGFRb+ NG2+Tbx18+cardiac pericytes/mural cells (PM) cultured from normal atria (PMnorm, n=6) and from ischemic failing hearts (PMfail, n=6) were compared. From a transcriptomic standpoint, biological processes and molecular functions associated with cell adhesion and actin cytoskeleton were differentially expressed by PMfail vs PMnorm. The morphological analysis of the two cell types showed that PMfail were significantly larger (2,455±160μm2 vs 3518±334μm2, p=0.04) and less polarized (aspect ratio: 3±0.9 vs 2±0.1, p=0.002) with respect to PMnorm. Consistently, PMfail showed a significantly smaller number of Paxillin+ focal adhesions/cell area and impaired migratory properties. Furthermore, PMfail showed contact inhibition of cell proliferation at significantly lower cell density with respect to PMnorm, paralleled by a significantly lower fraction of cells expressing YAP in their nuclei at a density of 500 cells/mm2 (28.1±12.7% vs 87.0±23.6%, p=0.029). Given the link between mechanotransduction, response to substrate stiffness and extracellular matrix composition, we evaluated the responses of PM plated on a soft (16kPa), intermediate (231kPa) and very hard (in order to GPa) polyacrylamide gels coated with two different fibronectin (FN) concentrations (1 and 25μg/mL). Atomic force microscopy measure of cell stiffness, showed that, while PMnorm significantly increase their intracellular stiffness (804±311Pa vs 1,320±394Pa, p=0.014) as a function of extracellular stiffness (soft vs very hard), PMfail do not. These results were paralleled by YAP and Myocardin Related Transcription Factor-A (MRTF-A) shuttling, that are translocated in the nuclei of PMnorm in response to substrate stiffness and fibronectin concentration significantly more than in the nuclei of PMfail cells. Analysis of CTGF, CYR61 and ANKRD1 gene expression corroborated these data. Finally, we demonstrated that serum deprivation, inhibitors of both actin polymerization (latrunculin-A), and Rho-associated Kinase (ROCK, Y23763) significantly inhibited the nuclear translocation of both YAP and MRTF-A and cell proliferation. Conversely, the MEK1/2 inhibitor I-1040 exerted opposite effects.
Conclusion
PM isolated from ischemic hearts are characterized by altered mechanotransduction properties that impair a correct nuclear translocation of the cotranscriptional regulators YAP and MRTF-A in response to environmental cues. Pharmacologic modulation of regulators of this pathway may revert the pathologic phenotype.
Collapse
Affiliation(s)
| | | | | | | | - S Sponga
- University Hospital Santa Maria della Misericordia, Cardiothoracic Surgery, Udine, Italy
| | - U Livi
- University Hospital Santa Maria della Misericordia, Cardiothoracic Surgery, Udine, Italy
| | - A Battistella
- Italian National Research Council (CNR), Istituto Officina dei Materiali (IOM), Trieste, Italy
| | - M Lazzarino
- Italian National Research Council (CNR), Istituto Officina dei Materiali (IOM), Trieste, Italy
| | | | | |
Collapse
|
3
|
Bernasconi C, Brusamolino E, Lazzarino M, Salvaneschi L, Isernia P, Magrini U. Lymphoblastic Lymphoma in Adults: A Study on 30 Patients Treated with Two Different Programs According to Bone Marrow Findings. Tumori 2018; 70:355-62. [PMID: 6591603 DOI: 10.1177/030089168407000410] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Thirty adult patients with lymphoblastic lymphoma were treated with two different programs according to bone marrow findings. Bone marrow positive patients were given an ALL-like program: vincristine, daunorubicin, cyclophosphamide and prednisone for induction of remission, CNS prophylaxis, continuous maintenance for three years and monthly reinductions. Bone marrow negative patients were given a conventional lymphoma program with CHOP-Bleo and limited RT on bulky mediastinum without CNS prophylaxis. The CR rate of the whole group was 54 % (62 % for ALL-treated versus 47 % for lymphoma-treated patients; not significantly different), with a median survival for remitters of 28.5 mos. Relapse-free survival of the whole group was 65 % at 12 and 25 % at 24 mos. Stage IV ALL-treated patients had a median survival of 16.5 versus 10 mos for stage IV lymphoma-treated ones (p = 0.05); the three-years survival was 24 and 10 %, respectively. No patients undergoing CNS prophylaxis (ALL-therapy) had neurological complications or late meningeal relapse. The better prognosis of ALL-treated patients, in spite of bone marrow positivity, argues in favor of an ALL-like therapy in all adult lymphoblastic lymphomas, in terms of CR rate, overall survival, and absence of CNS relapse. This therapy must be adopted irrespective of bone marrow findings, and regardless of how localized the lymphoma appears to be.
Collapse
|
4
|
Nappini S, Matruglio A, Naumenko D, Dal Zilio S, Bondino F, Lazzarino M, Magnano E. Graphene nanobubbles on TiO 2 for in-operando electron spectroscopy of liquid-phase chemistry. Nanoscale 2017; 9:4456-4466. [PMID: 28304018 DOI: 10.1039/c6nr09061c] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
X-Ray Photoelectron Spectroscopy (XPS) and X-Ray Absorption Spectroscopy (XAS) provide unique knowledge on the electronic structure and chemical properties of materials. Unfortunately this information is scarce when investigating solid/liquid interfaces and chemical or photochemical reactions under ambient conditions because of the short electron inelastic mean free path (IMFP) that requires a vacuum environment, which poses serious limitation on the application of XPS and XAS to samples present in the atmosphere or in the presence of a solvent. One promising approach is the use of graphene (Gr) windows transparent to both photons and electrons. This paper proposes an innovative system based on sealed Gr nanobubbles (GNBs) on a titanium dioxide TiO2 (100) rutile single crystal filled with the solution of interest during the fabrication stage. The GNBs were successfully employed to follow in-operando the thermal-induced reduction of FeCl3 to FeCl2 in aqueous solution. The electronic states of chlorine, iron and oxygen were obtained through a combination of electron spectroscopy methods (XPS and XAS) in different phases of the process. The interaction of various components in solution with solid surfaces constituting the cell was obtained, also highlighting the formation of a covalent C-Cl bond in the Gr structure. For the easiness of GNB fabrication and straightforward extension to a large variety of solutions, we envisage a broad application of the proposed approach to investigate in detail electronic mechanisms that regulate liquid/solid electron transfer in catalytic and energy conversion related applications.
Collapse
Affiliation(s)
- S Nappini
- IOM-CNR, Laboratorio TASC, S.S. 14-km 163.5, 34149 Basovizza, Trieste, Italy.
| | - A Matruglio
- IOM-CNR, Laboratorio TASC, S.S. 14-km 163.5, 34149 Basovizza, Trieste, Italy. and University of Trieste, Graduate School of Nanotechnology, Piazzale Europa 1, 34127 Trieste, Italy
| | - D Naumenko
- IOM-CNR, Laboratorio TASC, S.S. 14-km 163.5, 34149 Basovizza, Trieste, Italy.
| | - S Dal Zilio
- IOM-CNR, Laboratorio TASC, S.S. 14-km 163.5, 34149 Basovizza, Trieste, Italy.
| | - F Bondino
- IOM-CNR, Laboratorio TASC, S.S. 14-km 163.5, 34149 Basovizza, Trieste, Italy.
| | - M Lazzarino
- IOM-CNR, Laboratorio TASC, S.S. 14-km 163.5, 34149 Basovizza, Trieste, Italy.
| | - E Magnano
- IOM-CNR, Laboratorio TASC, S.S. 14-km 163.5, 34149 Basovizza, Trieste, Italy. and Department of Physics, University of Johannesburg, PO Box 524, Auckland Park, 2006, Johannesburg, South Africa
| |
Collapse
|
5
|
Varettoni M, Tedeschi A, Arcaini L, Pascutto C, Vismara E, Orlandi E, Ricci F, Corso A, Greco A, Mangiacavalli S, Lazzarino M, Morra E. Risk of second cancers in Waldenström macroglobulinemia. Ann Oncol 2012; 23:411-5. [DOI: 10.1093/annonc/mdr119] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
|
6
|
Ricci F, Tedeschi A, Vismara E, Montillo M, Nichelatti M, Varettoni M, Lazzarino M, Morra E, Greco A. The Impact of Advanced Age According to IPSSWM Cut-Off on the Outcome of Symptomatic and Asymptomatic Waldenström's Macroglobulinemia at Diagnosis. Clinical Lymphoma Myeloma and Leukemia 2011; 11:124-6. [DOI: 10.3816/clml.2011.n.027] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
7
|
Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24:1574-9. [PMID: 20631743 DOI: 10.1038/leu.2010.148] [Citation(s) in RCA: 271] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We studied the relationship between JAK2 (V617F) mutant allele burden and clinical phenotype, disease progression and survival in patients with polycythemia vera (PV). The percentage of granulocyte mutant alleles was evaluated using a quantitative real-time polymerase chain reaction-based allelic discrimination assay. Of the 338 patients enrolled in this prospective study, 320 (94.7%) carried the JAK2 (V617F) mutation. Direct relationships were found between mutant allele burden and hemoglobin concentration (P=0.001), white blood cell count (P=0.001), spleen size (P=0.001) and age-adjusted bone marrow cellularity (P=0.002), while an inverse relationship was found with platelet count (P<0.001). During the study period, eight patients progressed to post-PV myelofibrosis (MF) (all carrying >50% mutant alleles), while 10 patients developed acute myeloid leukemia (AML). The mutant allele burden was significantly related to the risk of developing myelofibrosis (P=0.029) and retained its significant effect also in multivariable analysis (P=0.03). By contrast, the risk of developing AML as well as that of thrombosis was not significantly related to mutant allele burden. Leukocytosis did not affect thrombosis, MF, leukemia or survival. In conclusion, a JAK2 (V617F) allele burden >50% represents a risk factor for progression to MF in PV.
Collapse
Affiliation(s)
- F Passamonti
- Division of Hematology, Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Paulli M, Arcaini L, Lucioni M, Boveri E, Capello D, Passamonti F, Merli M, Rattotti S, Rossi D, Riboni R, Berti E, Magrini U, Bruno R, Gaidano G, Lazzarino M. Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol 2009; 21:1189-1195. [PMID: 19858084 DOI: 10.1093/annonc/mdp454] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hepatitis C virus (HCV) infection has been linked to lymphoproliferative disorders. Marginal zone B-cell lymphoma (MZL) represents one of the most frequent lymphoma subtypes associated with HCV infection. We describe an unusual subset of HCV-associated MZL characterized by subcutaneous presentation. MATERIALS AND METHODS A series of 12 HCV-positive patients presenting with subcutaneous nodules that revealed lymphoma infiltration at biopsy. Molecular analysis of immunoglobulin heavy chain (IGH) gene rearrangement and FISH investigations for t(11;18)(q21;q21) and t(14;18)(q32;q21) were carried out in nine patients. RESULTS The 12 patients (median age 69.5 years), all with positive HCV serology, presented with single or multiple subcutaneous nodules resembling lipomas. Histologically the lesions showed lymphoid infiltrates, consistent with extranodal MZL of mucosa-associated lymphoid tissue (MALT). Functional IGH gene rearrangements were identified in nine tested patients, with somatic mutations in 82%, indicating a histogenesis from germinal center-experienced B cells. The t(11;18) was found in two of nine cases. Staging did not show any other lymphoma localization. In two patients, a response was achieved with antiviral treatment. Extracutaneous spread to MALT sites occurred in a case. CONCLUSIONS Our observations expand the spectrum of HCV-associated lymphomas to include a subset of extranodal MZL characterized by a novel primary 'lipoma-like' subcutaneous presentation and indolent clinical course.
Collapse
Affiliation(s)
- M Paulli
- Pathology Section, Department of Human Pathology.
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - M Lucioni
- Pathology Section, Department of Human Pathology
| | - E Boveri
- Pathology Section, Department of Human Pathology
| | - D Capello
- Division of Hematology, Department of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara
| | - F Passamonti
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - M Merli
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - S Rattotti
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| | - D Rossi
- Division of Hematology, Department of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara
| | - R Riboni
- Pathology Section, Department of Human Pathology
| | - E Berti
- Department of Dermatology, University of Milano-Bicocca, Milano
| | - U Magrini
- Pathology Section, Department of Human Pathology
| | - R Bruno
- Division of Tropical and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - G Gaidano
- Division of Hematology, Department of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara
| | - M Lazzarino
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
| |
Collapse
|
9
|
Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarino M. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 2009; 7:1587-9. [PMID: 19566793 DOI: 10.1111/j.1538-7836.2009.03531.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
10
|
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2009; 21:325-330. [PMID: 19633044 DOI: 10.1093/annonc/mdp329] [Citation(s) in RCA: 320] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND There are few data on the incidence and prognosis of extramedullary (EM) multiple myeloma (MM). There are concerns about a possible increase of EM relapses with the expanding use of high-dose therapy (HDT) and biological agents. PATIENTS AND METHODS The incidence of EM disease, its relationship with prior exposure to HDT or novel agents, and its prognostic impact were analyzed in 1003 MM patients. Based on the different therapies available, three periods were considered: 1971-1993, conventional-dose chemotherapy; 1994-1999, HDT for younger patients; and 2000-2007, introduction of novel agents. RESULTS Overall, 13% of patients had EM disease, 7% at diagnosis and 6% later. In the 2000-2007 period, there was a significant increase of EM involvement, at diagnosis (P = 0.02) and during follow-up (P = 0.03). The risk of EM spread was not significantly increased after HDT [hazard ratio (HR 0.6)], bortezomib (HR 1.62), or thalidomide/lenalidomide (HR 1.07). EM disease was associated with shorter overall (HR 3.26, P < 0.0001) and progression-free (HR 1.46, P = 0.04) survival. CONCLUSIONS The incidence of EM disease has increased, probably due to the availability of more sensitive imaging techniques and the prolongation of patients' survival. HDT or novel agents seem not to increase the risk of EM disease. EM involvement confers a poor prognosis.
Collapse
Affiliation(s)
- M Varettoni
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | - A Corso
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - G Pica
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - S Mangiacavalli
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - C Pascutto
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - M Lazzarino
- Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
| |
Collapse
|
11
|
Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F. Interferon alpha-2b as therapy for patients with Ph'-positive chronic myelogenous leukemia. Eur J Haematol Suppl 2009; 52:25-8. [PMID: 2279541 DOI: 10.1111/j.1600-0609.1990.tb00901.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We treated 114 Ph'+ chronic myeloid leukemia (CML) patients, 105 of whom were in chronic phase (CP) and 9 in accelerated phase (AP), with interferon alpha-2b (IFN alpha-2b) at intermittent or daily doses of 2-5 MU/m2. Of 35 previously untreated CP patients, 22 (63%) showed complete hematological response (CHR). This was significantly influenced by initial risk status. In 19 of the 22 CHR patients the median of Ph'+ cells decreased from 100% to 58%. Of 36 patients pretreated for less than 12 months, 19 (53%) achieved CHR. CHR rate was significantly related to IFN dose. Cytogenetic improvement was observed in 15 of the 19 patients, the median of Ph'+ cells dropping from 100% to 76%, with complete suppression of the Ph' chromosome in 1 case. Of the 34 patients pretreated for greater than 12 months, 21 (62%) obtained CHR. Cytogenetic improvement was observed in 10 cases, the median of Ph'+ cells declining from 100% to 66%. 1 of 9 AP patients obtained CHR. After a median follow-up of 32 months for the 63 CHR patients, 49 (78%) are still in disease control: 34 on IFN therapy, 15 after bone marrow transplantation (BMT) (13 autologous and 2 allogeneic). Blastic transformation (BT) occurred in 9 of 63 (14%) CHR patients and in 24 of 51 (47%) patients with less than CHR. IFN alpha-2b has proved to be an effective treatment for CML. Its combination with other treatment modalities represents an interesting and promising approach for future studies.
Collapse
Affiliation(s)
- G Alimena
- Department of Human Biopathology, University La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C, Inverardi D, Burgio VL, Castello A, Bernasconi C. Therapy of essential thrombocythemia with alpha-interferon: results and prospects. Eur J Haematol Suppl 2009; 52:15-21. [PMID: 2279539 DOI: 10.1111/j.1600-0609.1990.tb00899.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Conventional treatment of symptomatic essential thrombocythemia (ET) consists of long-term administration of myelosuppressive cytotoxic agents which, although efficacious in most cases, are associated with leukemogenic potential. Alpha-interferon (IFN) exerts a dose-dependent inhibitory influence on thrombopoiesis through a direct antiproliferative effect on megakaryocytic precursors. Therefore, it may provide a biologic, potentially non-mutagenic alternative to conventional cytotoxic treatments. At daily doses ranging from 1 to 5 M.U., alpha-IFN is efficacious in inducing a hematologic response in most patients with ET. Response to IFN is a gradual process. The median time to hematologic response varies from 1 to 3 months and a significant proportion of patients reach and maintain normal platelet counts with low doses (1-3 M.U./d). Normalization of marrow megakaryocytosis requires longer treatment (9-12 months). Also patients resistant to cytotoxic drugs may respond to alpha-IFN, suggesting a lack of cross-resistance between the two treatment modalities. Side-effects, although not severe, represents a limit to the administration of adequate doses of IFN in about 25% of cases. Once hematologic response has been obtained, both low-dose IFN and cytotoxic drugs are effective as maintenance. The full potentialities of alpha-IFN in ET in combination with cytotoxic drugs or with other cytokines need to be further investigated.
Collapse
Affiliation(s)
- M Lazzarino
- Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Passamonti F, Rumi E, Boveri E, Lazzarino M. Myelofibrotic transformation in essential thrombocythemia. Author reply. Haematologica 2009. [DOI: 10.3324/haematol.2008.002071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
14
|
Rumi E, Passamonti F, Pagano L, Ammirabile M, Arcaini L, Elena C, Flagiello A, Tedesco R, Vercellati C, Marcello AP, Pietra D, Moratti R, Cazzola M, Lazzarino M. Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. J Intern Med 2009; 265:266-74. [PMID: 18793248 DOI: 10.1111/j.1365-2796.2008.02014.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND High oxygen-affinity haemoglobin variants and 2,3-diphosphoglycerate (2,3-DPG) deficiency are inherited diseases generating low tissue oxygen tension and erythropoietin-driven erythrocytosis, that characterizes the clinical phenotype of patients. Level of blood p50 (the oxygen tension at which haemoglobin is 50% saturated) is used to recognize these conditions. OBJECTIVES To define the clinical utility of blood p50 measurement in the diagnosis of isolated erythrocytosis. SUBJECTS AND DESIGN Venous blood p50 measurement was included in the diagnostic work-up of 102 consecutive patients with isolated erythrocytosis besides blood cell count, arterial oxygen saturation, serum erythropoietin measurement and screening for JAK2 mutations. SETTING Haematological Outpatient Section at University Hospital. RESULTS Seven patients had relative erythrocytosis. Among 95 patients with absolute erythrocytosis, 4 (4.2%) had decreased p50 level. The extended study of family members revealed a familial inheritance. Two families had haemoglobin variants already described as Haemoglobin Malmö and Haemoglobin San Diego. In one family, the proband had a new high oxygen-affinity haemoglobin variant (Haemoglobin Safi) resulting from the transversion C-->A at codon 81 of the alpha2-globin gene. In the last family, a deficiency of 2,3-DPG was found. Within the 91 patients with normal p50 values, 46 (51%) had secondary erythrocytosis, 13 (14%) polycythemia vera and 32 (35%) idiopathic erythrocytosis. CONCLUSIONS This study suggests that the investigation of blood p50 level may be useful to define diagnosis in patients with isolated erythrocytosis.
Collapse
Affiliation(s)
- E Rumi
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Boveri E, Arcaini L, Merli M, Passamonti F, Rizzi S, Vanelli L, Rumi E, Rattotti S, Lucioni M, Picone C, Castello A, Pascutto C, Magrini U, Lazzarino M, Paulli M. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol 2009; 20:129-36. [DOI: 10.1093/annonc/mdn563] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Toffoli V, Esch F, Melli M, Cataruzza F, Pozzato A, Carrato S, Scoles G, Tormen M, Lazzarino M. Intrinsically aligned chemo-mechanical functionalization of twin cantilever structures. Nanotechnology 2008; 19:445502. [PMID: 21832731 DOI: 10.1088/0957-4484/19/44/445502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Mechanical oscillators became a main focus of research in recent years for potential applications in biomolecule detectors. We recently demonstrated the feasibility of a scheme based on twin cantilevers with a sensitivity down to the single molecule. This approach is extremely promising under the condition that the two terminals of the device can be functionalized with high selectivity and nanometric accuracy by linker molecules. Here we demonstrate a chemo-mechanical method to achieve the intrinsically aligned functionalization of two silicon surfaces, which can be separated by a gap controllable with nanometric precision. The chemical binding of the target molecules in the selected position is obtained through a cycloaddition reaction which exploits the reactivity of the freshly cleaved surfaces that form when the cantilever gap is created. The general validity of this approach is shown by the use in different chemical environments of two compounds with different reactive functional groups.
Collapse
Affiliation(s)
- V Toffoli
- CNR-INFM Laboratorio TASC, SS 14 km 163,5, 34012 Trieste, Italy. DEEI-Università di Trieste, Via Valerio, 10-34127 Trieste, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Orlandi EM, Baldanti F, Citro A, Pochintesta L, Gatti M, Lazzarino M. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy. Haematologica 2008; 93:1758-60. [DOI: 10.3324/haematol.13265] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
18
|
Corso A, Mangiacavalli S, Barbarano L, Montalbetti L, Mazzone A, Fava S, Varettoni M, Zappasodi P, Morra E, Lazzarino M. Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. Leuk Res 2008; 32:1085-90. [DOI: 10.1016/j.leukres.2007.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2007] [Revised: 11/08/2007] [Accepted: 11/08/2007] [Indexed: 10/22/2022]
|
19
|
Carella M, Orlandi E, Lazzarino M, Annunziata M, Ferrara F, Pungolino E, Morra E, Baratè C, Petrini M, Miglino M, Gobbi M. Multicenter experience with imatinib mesylate in 202 newly diagnosed chronic myeloid leukemia (CML) patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008; 19:1331-1335. [PMID: 18344536 DOI: 10.1093/annonc/mdn044] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND To evaluate the clinical outcome of patients with relapsed or refractory follicular lymphoma treated with immunochemotherapy, in vivo purging and high-dose therapy with autotransplant. PATIENTS AND METHODS Sixty-four patients were enrolled in the trial. Primary end point was progression-free survival (PFS). Secondary end points were the in vivo purging effect on stem-cell harvest and the impact of molecular response on the outcome. RESULTS At enrollment, 59% of patients were PCR+ for bcl-2 rearrangement in bone marrow (PCR-informative). After the immunochemotherapy, before mobilization, 97% obtained complete response or partial response and 87% of patients informative for bcl-2 were molecularly negative. Sixty-one patients proceeded to in vivo purging and peripheral blood stem cell (PBSC) mobilization with rituximab and high-dose AraC. The median number of CD34+ cells collected was 16.6 x 10(6)/kg. Of 33 PCR-informative patients, the harvests resulted in PCR- in all. Fifty-eight patients received high-dose therapy and autotransplant of in vivo purged PBSC. After a median follow-up of 3.5 years, 41 patients are in complete remission. Five-year PFS is 59%. CONCLUSION This study demonstrates that patients with advanced relapsed or refractory follicular lymphoma treated with immunochemotherapy, in vivo purging and autotransplant may obtain long-lasting PFS. In bcl-2-positive patients, in vivo purging allows the harvest of lymphoma-free PBSC. Absence of the bcl-2 rearrangement after autotransplant is associated with persistent clinical remission.
Collapse
Affiliation(s)
- L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia.
| | - F Montanari
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - E P Alessandrino
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - A Tucci
- Division of Hematology, Ospedali Civili, Brescia
| | - E Brusamolino
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - L Gargantini
- Division of Hematology, Niguarda Ca'Granda Hospital, Milano
| | - R Cairoli
- Division of Hematology, Niguarda Ca'Granda Hospital, Milano
| | - P Bernasconi
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - F Passamonti
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - M Bonfichi
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - V Zoli
- Division of Hematology, Ospedale S. Camillo, Roma, Italy
| | - C Bottelli
- Division of Hematology, Ospedali Civili, Brescia
| | - S Calatroni
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - D Troletti
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - M Merli
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - C Pascutto
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| | - I Majolino
- Division of Hematology, Ospedale S. Camillo, Roma, Italy
| | - G Rossi
- Division of Hematology, Ospedali Civili, Brescia
| | - E Morra
- Division of Hematology, Niguarda Ca'Granda Hospital, Milano
| | - M Lazzarino
- Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia
| |
Collapse
|
21
|
Vassallo C, Muzio F, Brazzelli V, Ester O, Lazzarino M, Borroni G. Primary dermal melanoma occurring in a patient affected by Philadelphia-positive chronic myeloid leukaemia. J Eur Acad Dermatol Venereol 2007; 21:1300-1. [PMID: 17894751 DOI: 10.1111/j.1468-3083.2007.02206.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
22
|
Vassallo C, Ardigò M, Brazzelli V, Zecca M, Locatelli F, Alessandrino PE, Lazzarino M, Corona S, Lanzerini P, Benazzo M, Fabbi M, Borroni G. Bartonella-related pseudomembranous angiomatous papillomatosis of the oral cavity associated with allogeneic bone marrow transplantation and oral graft-versus-host disease. Br J Dermatol 2007; 157:174-8. [PMID: 17553040 DOI: 10.1111/j.1365-2133.2007.07968.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Human infections due to Bartonella spp. are viewed as emerging diseases typical in, although not exclusive to, immunosuppressed patients, in particular those with AIDS, organ transplants and haematological malignancies. We describe four patients, three children and one adult, who developed vegetating papillomatous lesions exclusively on the oral mucosae. They shared a history of haematological malignancy and allogeneic bone marrow/stem cell transplantation, and later developed chronic graft-versus-host disease, also involving the oral mucosae. Histopathologically, the vegetating lesions were characterized by a diffuse neoangiogenesis, granulation-like tissue, and a mixed cell infiltrate predominantly composed of neutrophils. Gram-negative bacteria were found in the endothelial cells of the vessels in the deeper portion of the corium by electron microscopy. In three cases, DNA of B. henselae was detected by polymerase chain reaction (PCR), and confirmed by sequencing of the PCR products. All the lesions healed after systemic antibiotic therapy, although some recurred after months, and regressed again after systemic antibiotic treatment associated with conservative surgical excision.
Collapse
Affiliation(s)
- C Vassallo
- Department of Dermatology, Istituto di Ematologia, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Bernasconi P, Klersy C, Boni M, Cavigliano P, Calatroni S, Giardini I, Rocca B, Zappatore R, Caresana M, Dambruoso I, Lazzarino M, Bernasconi C. P109 Revised IPSS cytogenetic categories and WHO classification allow a better prognostic definition of patients with de novo myelodysplastic syndromes (MDS). Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70179-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21:1545-8. [PMID: 17410188 DOI: 10.1038/sj.leu.2404682] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Osteonecrosis of the jaw (ONJ) is a reported complication of bisphosphonate use. The incidence ranges between 6 and 13% and seems to be higher in people treated with zoledronic acid (ZA) than with pamidronate. We retrospectively evaluated the incidences of ONJ and skeletal-related events (SRE) in 106 patients with multiple myeloma divided in two groups according to the schedule of administration of bisphosphonates: 51 received monthly administrations until tolerated (group A, standard schedule), 55 were treated monthly during the first year and then every 3 months (group B, reduced schedule). The incidence of SRE was similar (15.1 per 100 person years in group A and 17.7 in group B). ONJ occurred in seven patients, six in group A and one in group B (P=0.049). The risk of ONJ was eight-fold lower with the reduced schedule than with the standard schedule. The only significant risk factor for ONJ was the type of bisphosphonate (P=0.006). The incidence of ONJ was significantly higher with ZA than with pamidronate + ZA (9.1 vs 1.6 per 100 person-years). No ONJ was observed in patients treated only with pamidronate. A reduced schedule of ZA may be safer than the standard schedule while maintaining anti-resorptive efficacy.
Collapse
Affiliation(s)
- A Corso
- Institute of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | |
Collapse
|
25
|
Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2006; 18:346-50. [PMID: 17071937 DOI: 10.1093/annonc/mdl388] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome. METHODS We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients. RESULTS HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus. CONCLUSIONS This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.
Collapse
Affiliation(s)
- L Arcaini
- Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, Pizzolo G, Rodeghiero F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006; 17:1434-40. [PMID: 16766591 DOI: 10.1093/annonc/mdl131] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) has been correlated to hepatitis C virus (HCV) infection in few series, but characteristics and outcome of these patients remain undefined. PATIENTS AND METHODS We analyzed 156 previously untreated consecutive HCV-positive patients with DLBCL observed between 1994 and 2004 in three major institutions from northern Italy. RESULTS Median age at presentation was 63 years and 8% of patients had DLBCL transformed from low-grade lymphomas. Spleen was the most frequently involved extranodal site, followed by liver and stomach. Treatment was delivered with cure-intent in 132 patients, while the remaining 24 patients received monochemotherapy or radiotherapy alone due to old age or seriously impaired hepatic function. Only five patients (4%) had to discontinue chemotherapy due to severe liver function impairment. The addition of rituximab did not seem to affect patients' tolerance to treatment. Five-year overall survival of the entire cohort was 72%, while 5-year progression-free survival (PFS) of the 132 patients treated with cure-intent was 51%. Hepatitis B virus co-infection, advanced Ann Arbor stage and nodal origin of the tumor resulted the strongest adverse prognostic factors. CONCLUSIONS Patients with HCV-positive DLBCL share distinctive clinical features. Future studies should prospectively evaluate the association between HCV and aggressive lymphomas.
Collapse
Affiliation(s)
- C Visco
- Department of Hematology, Ospedale S. Bortolo, Vicenza, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, Gallì A, Boggi S, Pietra D, Vanelli L, Marseglia C, Levi S, Arosio P, Lazzarino M, Cazzola M. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006; 20:549-55. [PMID: 16498394 DOI: 10.1038/sj.leu.2404142] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Erythroid dysplasia is the pathologic hallmark of myelodysplastic syndromes (MDS). To develop a quantitative flow-cytometry approach to its evaluation, we analyzed the expression of CD71, CD105, cytosolic H-ferritin (HF), cytosolic L-ferritin (LF) and mitochondrial ferritin (MtF) in erythroblasts from 104 MDS patients, 69 pathologic control patients and 19 healthy subjects. Six-parameter, 4-color flow cytometry was employed, and data were expressed as mean fluorescence intensity. Compared with pathologic and healthy controls, MDS patients had higher expression of HF (P < 0.001) and CD105 (P < 0.001), and lower expression of CD71 (P < 0.001). MtF was specifically detected in MDS with ringed sideroblasts, and there was a close relationship between its expression and Prussian blue staining (r = 0.89, P < 0.001). In vitro cultures of myelodysplastic hematopoietic progenitors showed that both HF and MtF were expressed at a very early stage of erythroid differentiation, and that MtF expression is specifically related to mitochondrial iron loading. A classification function based on expression levels of HF, CD71 and CD105 allowed us to correctly classify > 95% of MDS patients. This flow-cytometry approach provides an accurate quantitative evaluation of erythroid dysplasia and allows a reliable diagnosis of sideroblastic anemia, and may therefore be a useful tool in the work-up of patients with MDS.
Collapse
Affiliation(s)
- M G Della Porta
- Division of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Corso A, Mangiacavalli S, Nosari A, Castagnola C, Zappasodi P, Cafro AM, Astori C, Bonfichi M, Varettoni M, Rusconi C, Troletti D, Pascutto C, Morra E, Lazzarino M. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant 2005; 36:951-4. [PMID: 16184179 DOI: 10.1038/sj.bmt.1705166] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
From 2000 to 2004, 152 patients with multiple myeloma aged <or=65 years, enrolled in high-dose programs, were treated with two schedules of DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin): 106 patients (group I) were mobilized with the infusional version of DCEP (infusional-DCEP), and 46 patients (group II) with a shorter version (DCEP-short). The median number of CD34(+) cells collected was similar in the two groups as was the percentage of patients yielding >or=4 x 10(6) cells/kg. The proportion of patients in whom mobilization failed was similar in the two groups. The incidence of WHO grade III neutropenia was higher in group II, although the difference was not statistically significant; the percentage of patients requiring hospitalization for severe infections was similar in the two groups. The incidence of WHO grade IV thrombocytopenia did not differ between the two groups. The response rate was 72% in group I and 80% in group II with similar percentages of patients achieving good responses. DCEP-short is a good mobilizing regimen, sharing the same characteristics as infusional-DCEP: high mobilizing efficacy, low toxicity and good antitumor activity. This new schedule of DCEP does, however, allow complete outpatient management and so could be advantageously included in any high-dose therapy program.
Collapse
Affiliation(s)
- A Corso
- Division of Hematology, Istituto Scientifico Policlinico San Matteo, University of Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B, Zappatore R, Caresana M, Quarna J, Lazzarino M, Bernasconi C. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 2005; 19:1424-31. [PMID: 15920496 DOI: 10.1038/sj.leu.2403806] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The impact of clinical parameters, International Prognostic Scoring System (IPSS) scores/cytogenetic categories, and some single cytogenetic defects on overall survival (OS) and time to myelodysplastic syndromes (MDS)/AML progression (progression-free interval (PFI)) was evaluated in 331 MDS patients. Statistical analysis demonstrated that OS and PFI were significantly affected by all these parameters. Since single 7q- showed a better survival than the poor IPSS cytogenetic category (P=0.009), it was considered as a new prognostic entity ('modified IPSS categories'). In multivariate analysis OS was significantly influenced by age, marrow blast cell percentage, number of cytopenias and either modified or standard IPSS cytogenetic categories; hazard ratios for MDS/AML progression were influenced by all the former, except for age and cytopenias. Multivariate analysis of del(7)(q31q35) confirmed the results of univariate analysis, but the Akaike Information Criterion showed no difference in evaluating OS and PFI between the modified and standard IPSS cytogenetic grouping. In conclusion, (i) chromosome defects as grouped by IPSS and blast cell percentage are the most relevant parameters for predicting OS and PFI; (ii) the prognostic power of the IPSS cytogenetic grouping is not ameliorated by the introduction of del(7)(q31q35) as a new entity; (iii) complex karyotypes have a prognostic value independent of blast cell percentage.
Collapse
Affiliation(s)
- P Bernasconi
- Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, Maffioli M, Bernasconi P, Lazzarino M, Invernizzi R, Cazzola M. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005; 19:776-83. [PMID: 15789068 DOI: 10.1038/sj.leu.2403680] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The purpose of this study was to develop a flow cytometric approach to the evaluation of marrow dysplasia in myelodysplastic syndromes (MDS). We first studied a cohort of 103 MDS patients as well as 46 pathological and healthy controls. Flow cytometry data were expressed as percentage of positive cells. Analysis of erythroid cells showed higher proportions of immature cells (P < 0.001) and decreased levels of CD71 expression on nucleated red cells (P = 0.02) in MDS. Analysis of myeloid cells showed lower proportions of CD10+ and higher proportions of CD56+ granulocytes (P < 0.001), and increased ratios of immature to mature cells (P = 0.007). Since no single immunophenotype could accurately differentiate MDS from other conditions, we used discriminant analysis for generating erythroid and myeloid classification functions using combinations of immunophenotypic parameters. These functions were prospectively validated in a testing cohort of 69 MDS patients and 46 pathological controls. A diagnosis of MDS was obtained in 60/69 cases (87%). No false-positive results were noticed among controls. Significant correlations between values of these functions and both degree of morphological dysplasia and the International Prognostic Scoring System were found. These findings indicate that flow cytometry evaluation of marrow dysplasia is feasible and may be useful in the work-up of individual MDS patients.
Collapse
Affiliation(s)
- L Malcovati
- Division of Hematology, University of Pavia Medical School & IRCCS Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Passamonti F, Pietra D, Rumi E, Arcaini L, Della Porta MG, Malcovati L, Pascutto C, Lazzarino M, Cazzola M. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. Leukemia 2005; 19:888-9. [PMID: 15744342 DOI: 10.1038/sj.leu.2403700] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
32
|
Lazzarino M, Padovani M, Mori G, Sorba L, Fanetti M, Sancrotti M. Chemical composition of GaAs oxides grown by local anodic oxidation: a spatially resolved Auger study. Chem Phys Lett 2005. [DOI: 10.1016/j.cplett.2004.12.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Malcovati L, Della Portal M, Pascutto C, Maffioli M, Travaglino E, Bernasconi P, Invernizzi R, Lazzarino M, Cazzola M. P-14 Demographic and disease-related prognostic factors in myelodysplastic syndromes classified according to who criteria. Leuk Res 2005. [DOI: 10.1016/s0145-2126(05)80078-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
34
|
Vassallo C, Brazzelli V, Alessandrino PE, Varettoni M, Ardigò M, Lazzarino M, Borroni G. Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal. Br J Dermatol 2004; 151:579-86. [PMID: 15377343 DOI: 10.1111/j.1365-2133.2004.06072.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND Graft-versus-host-disease (GvHD) occurs in one-third or even half of bone marrow transplant (BMT) patients, involving three major target organs: gut, liver and skin. OBJECTIVES The histopathological and immunohistochemical features of normal-looking skin in oncohaematological patients on day 100 after BMT were studied to find a possible relationship between the histopathological findings and clinical variables (history or clinical evidence of GvHD, previous therapeutic regimens or infections). METHODS Fifty-one Caucasian oncohaematological patients, who had had an allogenic BMT, had a biopsy taken from normal-looking skin in nonsun-exposed areas (buttocks or the lumbar region), around the 100th day after BMT. The histology was studied, and the influence of clinical variables on the development of every different histopathological pattern was evaluated through statistical analysis. RESULTS Histopathological analysis based on morphological criteria revealed the presence of three different patterns: a postinflammatory pattern (45%), changes similar to grade I and II of GvHD (31%) and no significant changes (24%). Statistical analysis revealed that only the presence of peaks of cytomegalovirus (CMV) antigen in the blood within 100 days from BMT was significantly associated with the pattern of GvHD-like changes. CONCLUSIONS Normal-looking skin in 76% of BMT patients is not necessarily histologically normal. The pattern with more prominent changes, the GvHD-like pattern, has been found to be associated with a more frequent history of CMV antigen in the blood within 100 days from BMT.
Collapse
Affiliation(s)
- C Vassallo
- Department of Dermatology,University of Pavia, Policlinico S.Matteo-IRCCS, Piazzale Golgi 2, 27100 Pavia, Italy.
| | | | | | | | | | | | | |
Collapse
|
35
|
Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplant 2004; 34:1039-45. [PMID: 15516936 DOI: 10.1038/sj.bmt.1704717] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m(2) over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6 U, range 1-23), and all received platelets (median 4 U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.
Collapse
Affiliation(s)
- E P Alessandrino
- Bone Marrow Transplantation Unit, Division of Haematology, IRCCS Policlinico San Matteo, Viale Golgi N. 19, Pavia 27100, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Morra E, Cesana C, Klersy C, Barbarano L, Varettoni M, Cavanna L, Canesi B, Tresoldi E, Miqueleiz S, Bernuzzi P, Nosari AM, Lazzarino M. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia 2004; 18:1512-7. [PMID: 15322559 DOI: 10.1038/sj.leu.2403442] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We evaluated the prognostic features of 384 asymptomatic IgM-monoclonal gammopathies (aIgM-MGs) and 74 IgM-related disorders (IgM-RDs), two clinically distinct groups as proposed by the Second International Workshop on Waldenström's Macroglobulinemia (WM). The cumulative probability of evolution to lymphoid malignancy at 5 and 10 years was 8% (95% CI, 5-13%) and 29% (95% CI, 21-38%), respectively, in aIgM-MGs; it was 9% (95% CI, 4-20%) and 16% (95% CI, 7-31%), respectively, in IgM-RDs (P=0.26). At a median follow-up of 45 months (12-233), 45 aIgM-MGs (11.7%) evolved to symptomatic WM (n=41), non-Hodgkin's lymphoma (NHL) (n=2), IgM multiple myeloma (n=1), and primary amyloidosis (n=1). At a median follow-up of 60 months (13-195), seven IgM-RDs (9.5%) evolved to symptomatic WM (n=6), and B-chronic lymphocytic leukaemia (n=1). At univariate analysis, in aIgM-MGs bone marrow lymphoplasmacytic infiltration, high erythrocyte sedimentation rate (ESR), haemoglobin level, IgM size, and lymphocytosis significantly correlated with evolution probability. At multivariate analysis, the latter two parameters strongly correlated with prognosis, haemoglobin being associated with a trend for a higher progression risk. In IgM-RDs IgM size, neutropenia, lymphocytosis, detectable Bence Jones proteinuria, and high ESR were associated with evolution probability. In conclusion, asymptomatic IgM-MGs and IgM-RDs are distinct clinical entities with similar probability of transformation to lymphoid malignancy.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Amyloidosis/diagnosis
- Amyloidosis/immunology
- Amyloidosis/metabolism
- Biological Evolution
- Biomarkers, Tumor/metabolism
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin M/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Lymphoma, Non-Hodgkin/diagnosis
- Lymphoma, Non-Hodgkin/immunology
- Male
- Middle Aged
- Monoclonal Gammopathy of Undetermined Significance/diagnosis
- Monoclonal Gammopathy of Undetermined Significance/immunology
- Multiple Myeloma/diagnosis
- Multiple Myeloma/immunology
- Predictive Value of Tests
- Prognosis
- Survival Rate
- Waldenstrom Macroglobulinemia/diagnosis
- Waldenstrom Macroglobulinemia/immunology
Collapse
Affiliation(s)
- E Morra
- Division of Hematology Niguarda Ca' Granda Hospital, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Corso A, Dovio A, Rusconi C, Sartori ML, Klersy C, Varettoni M, Mangiacavalli S, Zappasodi P, Ventura M, Angeli A, Lazzarino M. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia 2004; 18:1555-7. [PMID: 15241438 DOI: 10.1038/sj.leu.2403429] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
38
|
Corso A, Lorenzi A, Terulla V, Airò F, Varettoni M, Mangiacavalli S, Zappasodi P, Rusconi C, Lazzarino M. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83:588-91. [PMID: 15235749 DOI: 10.1007/s00277-004-0891-6] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2003] [Accepted: 05/10/2004] [Indexed: 12/28/2022]
Abstract
Deep venous thrombosis (DVT) has been variably reported in multiple myeloma patients during treatment with thalidomide alone or in combination with chemotherapy or dexamethasone. With the aim of investigating this complication, we performed, on a cohort of 13 relapsed refractory MM patients treated with low-dose thalidomide (100 mg/day) and dexamethasone (20 mg p.o./day for 4 days every 2 weeks), a serial evaluation of different laboratory parameters implicated in DVT. No significant abnormalities in all genetic, serologic, or plasmatic parameters studied were registered, apart from thrombomodulin which showed significant variations between baseline and 1st-month values and 1st- and 3rd-month values. In conclusion, the evidence of significant variations of thrombomodulin values in the 1st month of therapy, which is considered to involve the highest risk of thrombosis, might support a role for thrombomodulin in this complex mechanism.
Collapse
Affiliation(s)
- A Corso
- Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004; 34:175-9. [PMID: 15170171 DOI: 10.1038/sj.bmt.1704551] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of HD chemotherapy and autotransplant. After two courses of debulking immunochemotherapy with Rituximab, Vincristine and Cyclophosphamide, we used a combination of Rituximab, HD cytarabine and granulocyte colony-stimulating factor for peripheral blood stem cells (PBSC) mobilization. The median number of CD34+ cells collected was 14.69 x 10(6)/kg (range 5.74-73.2). Monitoring of peripheral CD19+ and CD20+ B cells prior to and throughout the purging period showed that a treatment with Rituximab, Vincristine and Cyclophosphamide results in a profound depletion of B cells in peripheral blood. B-cell depletion persists during mobilization with Rituximab and HD cytarabine allowing a collection of PBSC free of B cells (median CD19+ and CD20+ cells counts 0%). Of nine patients PCR positive for bcl-2 or bcl-1 in blood and marrow at the start of immunochemotherapy, all showed PCR-negative PBSC. In conclusion, in patients with indolent lymphoma, the concurrent administration of Rituximab and HD cytarabine is a safe and efficient method to obtain in vivo purged PBSC. Immunochemotherapy prior to mobilization produces B-cell depletion and seems to be a useful preparative step.
Collapse
MESH Headings
- Adult
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD34/analysis
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- B-Lymphocytes/drug effects
- B-Lymphocytes/immunology
- Bone Marrow Purging/methods
- Cytarabine/therapeutic use
- Female
- Hematopoietic Stem Cell Mobilization/methods
- Humans
- Immunophenotyping
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/therapy
- Lymphoma, Mantle-Cell/drug therapy
- Lymphoma, Mantle-Cell/therapy
- Male
- Middle Aged
- Peripheral Blood Stem Cell Transplantation/methods
- Rituximab
- Salvage Therapy/methods
- Transplantation, Autologous
Collapse
Affiliation(s)
- L Arcaini
- Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90:372-6. [PMID: 14735179 PMCID: PMC2409547 DOI: 10.1038/sj.bjc.6601460] [Citation(s) in RCA: 114] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised studies, we retrospectively analysed: (a) the effectiveness of two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) and (b) the role of mediastinal involved-field radiotherapy (IF-RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated in 13 Italian institutions with CHOP (43) or MACOP-B/VACOP-B (95). The two groups of patients were similar as regard to age, gender, presence of bulky mediastinal mass, pleural effusion, stage and international prognostic indexes category of risk. Overall, 75.5% of patients in CR received IF-RT as consolidation. Complete remission was 51.1% in the CHOP group and 80% in MACOP-B/VACOP-B (P<0.001). Relapse occurred in 22.7% of CHOP- and in 9.2% of MACOP-B/VACOP-B-treated patients (n.s.). Event-free patients were 39.5% in CHOP and 75.7% in the MACOP-B/VACOP-B group (P<0.001). The addition of IF-RT as consolidation improved the outcome, irrespectively of the type of chemotherapy (P=0.04). At a multivariate analysis, achievement of CR (P<0.0001) and type of CT (MACOP-B/VACOP-B) retained the significance for OS (P=0.008) and EFS (P=0.03). In our experience, MACOP-B/VACOP-B appears to positively influence OS and EFS in patients affected by PMLBCL, as compared to CHOP. Consolidation IF-RT on mediastinum further improves the outcome of CR patients.
Collapse
Affiliation(s)
- G Todeschini
- Department of Hematology, Verona University, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Lucioni M, Boveri E, Rosso R, Benazzo M, Necchi V, Danova M, Incardona P, Franco C, Viglio A, Riboni R, Lazzarino M, Magrini U, Canevari A, Paulli M. Lymph node reticulum cell neoplasm with progression into cytokeratin-positive interstitial reticulum cell (CIRC) sarcoma: a case study. Histopathology 2003; 43:583-91. [PMID: 14636259 DOI: 10.1111/j.1365-2559.2003.01725.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
AIMS To detail on sequential biopsies the morphological and immunohistochemical features of a case of primary lymph nodal fibroblastic reticulum cell (FBRC) tumour which progressed into a clinically aggressive cytokeratin-positive interstitial reticulum cell (CIRC) sarcoma. METHODS AND RESULTS A 70-year-old female underwent surgical excision of an enlarged submandibular lymph node. The nodal architecture was effaced by a neoplastic proliferation of medium to large cells, round to oval to spindle in shape, growing in a storiform pattern. The tumour stained for vimentin, CD68, factor XIIIa, alpha1-antitrypsin, fascin and actin. Dendritic and endothelial cell markers were negative. A diagnosis of FBRC tumour was made by combining pathological and clinical data. The patient received no therapy but 5 months later the tumour relapsed, exhibiting a deceptively pleomorphic cytology, phenotypic changes (strong cytokeratin positivity), intense p53 expression and aggressive clinical course with fatal outcome. In-situ hybridization for Epstein-Barr virus was negative. CONCLUSIONS We speculate that the morphological changes and p53 expression of the relapsing neoplasm might reflect tumour cell dedifferentiation, in keeping with the aggressive clinical course. The intense p53 expression suggests that this oncoprotein might also play a role in reticulum cell tumorigenesis.
Collapse
Affiliation(s)
- M Lucioni
- Pathology Section, Department of Human Pathology, I.R.C.C.S. Policlinico S. Matteo, University of Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Bernasconi P, Cavigliano PM, Boni M, Calatroni S, Klersy C, Giardini I, Rocca B, Crosetto N, Caresana M, Lazzarino M, Bernasconi C. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 2003; 17:2107-12. [PMID: 12931223 DOI: 10.1038/sj.leu.2403108] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Conventional cytogenetics (CC) at clinical diagnosis shows a normal karyotype in 40-60% of de novo myelodysplastic syndromes (MDSs). Fluorescence in situ hybridization (FISH) might detect occult aberrations in these patients. Therefore, we have used FISH to check 57 MDS patients who were karyo-typically normal on CC. At clinical diagnosis, FISH revealed a clonal abnormality in 18-28% interphase cells from nine patients, five of whom also presented the same defect on metaphase FISH. In five out of nine patients, the occult defect effected a change in the international prognostic scoring system (IPSS). An abnormal FISH pattern was significantly correlated with marrow blast cell percentage (P<10(-3)) and IPSS (P<10(-3)). Patients with an occult abnormality showed an overall survival and event-free survival significantly inferior in comparison to those of patients with normal FISH (P<10(-3), P<10(-3)). Death and AML progression were 15- and eight-fold more frequent in FISH abnormal patients. In conclusion, occult defects (1) are revealed in about 15% of CC normal MDS patients, (2) are overlooked by CC either because of the poor quality of metaphases or their submicroscopic nature, (3) are clinically relevant as they may cause a change in the IPSS category and may identify a fraction of CC normal patients with an unfavorable clinical outcome.
Collapse
Affiliation(s)
- P Bernasconi
- Division of Hematology, Policlinico San Matteo IRCCS, University of Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Corso A, Zappasodi P, Pascutto C, Bosoni T, Mangiacavalli S, Lorenzi A, Rusconi C, Lazzarino M. Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications. Ann Hematol 2003; 82:487-491. [PMID: 12838370 DOI: 10.1007/s00277-003-0699-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2003] [Accepted: 05/24/2003] [Indexed: 10/26/2022]
Abstract
Renal failure is one of the worst complications occurring in multiple myeloma (MM) patients. It does not affect survival if reverted by a prompt chemotherapy before the damage becomes irreversible; therefore, the early diagnosis of renal dysfunction is crucial. High and low molecular weight urinary proteins have proved to be helpful in diagnosing initial renal damage since they are more sensitive than urea and creatinine serum levels or creatinine clearance. We studied the renal function of 111 MM patients through serum creatinine, urea, urinary IgG, alpha(1)-microglobulin (alpha(1)-M), and albumin (Alb). Two successive controls were made in a subset of 30 patients, categorized in three groups (improved, stable, worsened) according to the behavior of tumor burden markers (bone marrow plasmacytosis, monoclonal component, and beta(2)-microglobulin). In every group, we evaluated the behavior of urinary proteins. Renal dysfunction evaluated with serum parameters was present in 19 patients (17%), while if studied with urinary proteins was revealed in 71 patients (64.5%). Urinary proteins statistically correlated with each other. They correlated with creatinine, IgG, and alpha(1)-M also with urea. By contrast, they showed a variable correlation with clinical parameters: alpha(1)-M correlated with bone marrow plasmacytosis (BMPC) ( p=0.02) and beta(2)-M ( p=0.000001), IgG with all three disease parameters (MC p=0.0005, BMPC p=0.009, beta(2)-M p=0.007), and Alb only with beta(2)-M ( p=0.0004). In the subset of 30 patients followed with two successive controls, urinary proteins showed a parallel behavior with the indices of tumor burden. In conclusion, IgG, alpha(1)-microglobulin, and albumin are reliable and sensitive to precociously reveal renal damage, and we recommend their routine use for the definition and monitoring of renal function in multiple myeloma patients, mainly those in early stage, to better identify initial signs of progression.
Collapse
Affiliation(s)
- A Corso
- Institute of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100, Pavia, Italy.
| | - P Zappasodi
- Institute of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100, Pavia, Italy
| | - C Pascutto
- Institute of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100, Pavia, Italy
| | - T Bosoni
- Department of Biochemistry, Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - S Mangiacavalli
- Institute of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100, Pavia, Italy
| | - A Lorenzi
- Institute of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100, Pavia, Italy
| | - C Rusconi
- Institute of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100, Pavia, Italy
| | - M Lazzarino
- Institute of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100, Pavia, Italy
| |
Collapse
|
44
|
Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F, Volpe G, Pistorio A, Giardini I, Rocca B, Caresana M, Lazzarino M, Bernasconi C. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 2002; 16:2078-83. [PMID: 12357360 DOI: 10.1038/sj.leu.2402638] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2001] [Accepted: 05/05/2002] [Indexed: 01/08/2023]
Abstract
ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous ((32)P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the long-term safety of hydroxyurea (HU). Pipobroman (PI), a well tolerated and simple to use drug, constitutes a valid alternative to those cytoreductive treatments. The present study reports on 155 ET patients treated at our institution from 1985 to 1995, and monitored until December 2000. A good control of thrombocytosis was achieved with PI as the only treatment in 106 patients and with HU in 23 patients. Twenty-six patients received no treatment. After a median follow-up of 104 months, seven patients (four treated with HU, and three with PI) developed AML whereas one patient treated with PI developed MDS. A significant difference in progression-free survival was observed between HU- and PI-treated patients (P = 0.004). A short-arm deletion of chromosome 17 was most frequently detected in HU-treated patients, while a long-arm trisomy of chromosome 1 and a monosomy 7q were seen in PI-treated patients. No TP53 mutation was discovered in the six patients studied (two HU-treated and four PI-treated). We conclude that these cytogenetic abnormalities are not linked to the natural history of the disease, but rather that they might be induced by the cytoreductive treatment.
Collapse
Affiliation(s)
- P Bernasconi
- Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Policlinico San Matteo IRCCS, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
Besides bone pain, pathologic fractures, anaemia, and recurrent infectious diseases, renal failure is one of the most serious complications in multiple myeloma patients. Its incidence is generally underestimated because of the low reliability of the parameters routinely used for the evaluation of renal dysfunction. Other laboratory tests in the literature are reported to be more suitable to better define the extension of the renal impairment, namely urinary proteins or creatinine clearance. We here report on the clinical implication of urinary parameters in defining the renal function in myeloma patients.
Collapse
Affiliation(s)
- A Corso
- Division of Hematology, University of Pavia, IRCCS Policlinico San Matteo, Italy.
| | | | | |
Collapse
|
46
|
Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I, Regazzi MB, Morra E. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116:229-35. [PMID: 11841421 DOI: 10.1046/j.1365-2141.2002.03256.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Options for relapsed/refractory indolent lymphoma include chemotherapy, immunotherapy and high-dose therapy with autologous support. The best combination of these approaches, however, is not defined. We treated 10 patients with relapsed/refractory follicular (n = 7) or mantle cell lymphoma (n = 3) using chemotherapy, immunotherapy, high-dose therapy and autotransplant in a sequence of four phases, each designed to play a specific role in tumour eradication. After the debulking with VACOP-B (doxorubicin, cyclophosphamide, etoposide, vincristine, prednisone, bleomycin) (phase 1), 9/10 patients responded but none achieved a molecular response. After the immuno-chemotherapy phase, which combined Rituximab with vincristine and cyclophosphamide, seven patients were in complete response (CR) and three in good partial response (PR), and all those with a molecular marker of disease showed a disappearance of the signal from marrow and blood. Phase 3, which coupled high-dose cytarabine with Rituximab, was effective in mobilizing an adequate number of progenitor cells that were polymerase chain reaction negative in all informative cases. Phase 4 consisted of high-dose therapy with autologous support followed by two doses of Rituximab. Autograft was performed in nine patients. The haematopoietic recovery was as expected. This sequence of chemotherapy, immuno-chemotherapy, stem cell mobilization with in vivo purging and autotransplant, organized in four blocks of treatment, was simple to administer and devoid of toxic effects. It permits rapid attainment of clinical and molecular response and enables the harvest of lymphoma-free peripheral blood progenitor cells even in heavily pretreated patients with relapsed or refractory disease.
Collapse
Affiliation(s)
- M Lazzarino
- Division of Hematology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Giazotto F, Pingue P, Beltram F, Lazzarino M, Orani D, Rubini S, Franciosi A. Resonant transport in Nb /GaAs /AlGaAs heterostructures: realization of the de Gennes-Saint-James model. Phys Rev Lett 2001; 87:216808. [PMID: 11736368 DOI: 10.1103/physrevlett.87.216808] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2001] [Indexed: 05/23/2023]
Abstract
Resonant transport is demonstrated in a hybrid superconductor-semiconductor heterostructure junction grown by molecular beam epitaxy on GaAs. This heterostructure realizes the model system introduced by de Gennes and Saint-James in 1963 [P. G. de Gennes and D. Saint-James, Phys. Lett. 4, 151 (1963)]. At low temperatures a single marked resonance peak is shown superimposed to the characteristic Andreev-dominated subgap conductance. The observed magnetotransport properties are successfully analyzed within the random matrix theory of quantum transport, and ballistic effects are included by directly solving the Bogoliubov-de Gennes equations.
Collapse
Affiliation(s)
- F Giazotto
- NEST-INFM and Scuola Normale Superiore, I-56126 Pisa, Italy
| | | | | | | | | | | | | |
Collapse
|
48
|
Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001; 28:835-9. [PMID: 11781643 DOI: 10.1038/sj.bmt.1703240] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2001] [Accepted: 08/13/2001] [Indexed: 11/08/2022]
Abstract
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) has proved to be an effective salvage therapy for refractory-relapsed MM patients. Little is known, however, about its potential as mobilizing therapy. The aim of this study was to evaluate the efficacy of DCEP in mobilizing PBSC and to define its toxicity. Fifty-five MM patients received DCEP followed by G-CSF as part of high-dose programs including autologous transplantation. At the time of mobilization, 40 patients had previously received VAD only, and 15 alkylating agents. Mobilization was successful (minimum number of CD34(+) cells 2 x 10(6)/kg) in 48/55 patients (87%), and 41/55 patients (75%) collected >4 x 10(6)/kg CD34(+) cells. Of the seven patients who did not mobilize stem cells, five (71%) had been previously exposed to alkylating agents. The median number of CD34(+) cells harvested was 5.8 x 10(6)/kg (range 2.1-22.4). There was no treatment-related mortality. The side-effects of DCEP were always tolerable. No neutropenia <1000/microl nor thrombocytopenia <50,000/microl were observed. No patient required transfusion as a consequence of therapy, or hospitalization for septic complications. In conclusion, DCEP, in addition to its demonstrated anti-tumor activity, is an effective regimen for mobilizing peripheral blood progenitor cells in myeloma patients, with little or no side-effects. These properties render DCEP a useful regimen for the debulking and mobilization phase of high-dose programs for multiple myeloma.
Collapse
Affiliation(s)
- M Lazzarino
- Division of Hematology, IRCCS Policlinico S Matteo, University of Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Arcaini L, Cerani P, Lorenzi A, Lazzarino M. A young woman with microcytic anemia and hypertransaminasemia. Haematologica 2001; 86:E24. [PMID: 11602431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
|
50
|
Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Bonfichi M, Pagnucco G, Malcovati L, Varettoni M, Lazzarino M, Bernasconi C. Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Ann Hematol 2001; 80:521-4. [PMID: 11669300 DOI: 10.1007/s002770100344] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Standard conditioning for allogeneic bone marrow transplantation induces high transplant-related mortality (TRM) in patients with a poor performance status. Less intensive regimens have been tested to reduce the TRM; our purpose was to evaluate the feasibility and tolerability of a new combination: thiotepa and fludarabine (TT-FLUDA). Six patients received 5 mg thiotepa/kg daily from day -8 to -7 and 25 mg fludarabine/m2 daily from day -6 to -2 followed by an allogeneic peripheral blood progenitor cell infusion; three of these patients with signs of overt leukemia received 18 mg idarubicin/m2 i.v. at day -12. Graft-versus-host-disease (GVHD) prophylaxis was performed i.v. with 1 mg cyclosporine A/kg per day from day -5 to the day of marrow engraftment, then 6 mg/kg per day orally up to day +100, and 10 mg methotrexate/m2 at day +1, and 8 mg/m2 at days +3, +6, and +11. Chimerism was studied with fluorescent in situ hybridization for sex chromosomes (XY-FISH) and minisatellite polymerase chain reaction (PCR) at days +30, +100, +180, and +360. Engraftment was achieved in all cases with complete donor chimerism in all but one patient who had refractory acute leukemia. No major toxicity was noticed; only one patient died at day +51 of acute GVHD because of early cyclosporine A discontinuation. One patient with refractory non-Hodgkin's lymphoma (NHL) had a testicular relapse at day +180. Three patients (one with mantle cell lymphoma, two with acute myeloid leukemia) are still in continuous complete remission (CR) with complete donor chimerism at days +180, +210, and +450, respectively. TT-FLUDA seems to be well tolerated, allowing engraftment and stable donor chimerism in patients who are poor candidates for conventional conditioning regimens.
Collapse
Affiliation(s)
- E P Alessandrino
- Centro Trapianti di Midollo Osseo, Istituto di Ematologia, IRCCS Policlinico S. Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|